Scaling from a T-flask to a bioreactor isn't just increasing volume; it's a fundamental shift in the biological context. Changes in cell density, mass transfer, and mechanical stress rewire cell signaling. Therefore, understanding and respecting the cell's biology must be the primary design input for successful scale-up.
Related Insights
For startups adopting AI, the most effective starting point is not a massive overhaul. Instead, focus on a single, high-value process unit like a bioreactor. Use its clean, organized data to apply simple predictive models, demonstrate measurable ROI, and build organizational confidence before expanding.
By training on multi-scale data from lab, pilot, and production runs, AI can predict how parameters like mixing and oxygen transfer will change at larger volumes. This enables teams to proactively adjust processes, moving from 'hoping' a process scales to 'knowing' it will.
As a company grows, its old operational systems and processes ('plumbing') become obsolete. True scaling is not about addition; it's about reinvention. This involves systematically removing outdated processes designed for a smaller scale and replacing them entirely.
The most significant breakthroughs will no longer come from traditional wet lab experiments alone. Instead, progress will be driven by the smarter application of AI and simulations, with future bioreactors being as much digital as they are physical.
The silkworm platform changes the manufacturing paradigm from "scaling up" to "scaling out." Instead of building larger, more expensive bioreactors, production is increased simply by using more pupae. This model offers greater flexibility to adapt to demand, lowers infrastructure costs, and reduces the engineering risks associated with traditional scale-up.
Silkworm biomanufacturing offers incredible production density, with one pupa producing 10-20 mg of protein. Scaling requires simply adding more pupae ('scaling out') rather than building larger facilities ('scaling up'), enabling decentralized, small-footprint manufacturing.
Unlike most biotechs that start with researchers, CRISPR prioritized hiring manufacturing and process development experts early. This 'backwards' approach was crucial for solving the challenge of scaling cell editing from lab to GMP, which they identified as a primary risk.
CEO Marc Salzberg clarifies that for their recombinant protein, the difficulty was not in the manufacturing itself but in designing the complex upstream process, purification, and analytics. This innovation became a core asset and "claim to fame," allowing them to transfer a well-defined process to a capable CDMO for scaling.
A 3D model is considered "advanced" when it's a bioactive system recreating a tissue's microenvironment. It's not just about three-dimensional growth; cells must both influence and be influenced by their surroundings, including architecture, diffusion gradients, and mechanical cues, to be truly representative.
There's no universal bioreactor setting for 3D tissue models. Each tissue type has unique biological needs. For instance, neural cells require minimal shear stress and low oxygen, whereas liver cells need rigorous perfusion flow to maintain metabolic competence, mandating highly tailored process design for each model.